Name:	ions_AdditionalAmountOfCommonStockRequiredToBePurchasedInTheFuture
Namespace Prefix:	ions_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- References

No definition available.

Name:	ions_CollaborativeArrangementAndLicensingAgreementAbstract
Namespace Prefix:	ions_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

The amount of consideration allocated to delivery of the active pharmaceutical ingredient (API) for the drug under the collaboration agreement.

No definition available.

Name:	ions_ConsiderationAllocatedToDeliveryOfActivePharmaceuticalIngredient
Namespace Prefix:	ions_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

The amount of consideration allocated to development activities for the drug under the collaboration agreement.

No definition available.

Name:	ions_ConsiderationAllocatedToDevelopmentActivities
Namespace Prefix:	ions_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

The amount of consideration allocated to development activities and delivery of the active pharmaceutical ingredient (API) for the drug(s) under the collaboration agreement.

No definition available.

Name:	ions_ConsiderationAllocatedToDevelopmentServicesAndDeliveryOfActivePharmaceuticalIngredients
Namespace Prefix:	ions_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

The amount of consideration allocated to equity under the collaboration agreement.

No definition available.

Name:	ions_ConsiderationAllocatedToEquity
Namespace Prefix:	ions_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

Total consideration under the collaborative arrangement, including an upfront payment, the premium paid for the purchase of stock, and the potential premium received if stock is purchased in the future at a premium.

No definition available.

Name:	ions_ConsiderationUnderTheCollaborativeArrangement
Namespace Prefix:	ions_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

The license fee payment receivable per drug under the collaboration agreement.

No definition available.

Name:	ions_LicenseFeePaidPerDrug
Namespace Prefix:	ions_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

The maximum amount of payments receivable for commercialization milestones under the collaboration agreement.

No definition available.

Name:	ions_MaximumAmountOfPaymentsReceivableForCommercializationMilestones
Namespace Prefix:	ions_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

The maximum amount of payments receivable for development milestones under the collaboration agreement.

No definition available.

Name:	ions_MaximumAmountOfPaymentsReceivableForDevelopmentMilestones
Namespace Prefix:	ions_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

The maximum amount of payments receivable for milestones under the collaboration agreement.

No definition available.

Name:	ions_MaximumAmountOfPaymentsReceivableForMilestones
Namespace Prefix:	ions_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

The maximum amount of payments receivable for regulatory milestones under the collaboration agreement.

No definition available.

Name:	ions_MaximumAmountOfPaymentsReceivableForRegulatoryMilestones
Namespace Prefix:	ions_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

The next potential milestone payment to be earned under the collaboration agreement.

No definition available.

Name:	ions_NextPotentialMilestonePayment
Namespace Prefix:	ions_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

The number of drugs with an exclusive option that could be exercised to develop and commercialize the drug and a license fee is paid under the collaboration agreement. The collaboration partner will assume all further global development, regulatory and commercialization activities for the licensed drug.

No definition available.

Name:	ions_NumberOfDrugsWithExclusiveOptionThatCouldBeExercised
Namespace Prefix:	ions_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

The percentage of license fees, milestone payments and royalties paid as sublicense fee under the collaboration agreement.

No definition available.

Name:	ions_PercentageOfLicenseFeesMilestonePaymentsAndRoyaltiesPaidAsSublicenseFee
Namespace Prefix:	ions_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

The amount of the upfront payment received during the period under the collaboration agreement that was paid as a sublicense fee.

No definition available.

Name:	ions_PortionOfUpfrontPaymentPaidAsASublicenseFee
Namespace Prefix:	ions_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

The amount of the upfront payment received during the period under the collaboration agreement that was retained by the entity.

No definition available.

Name:	ions_PortionOfUpfrontPaymentRetained
Namespace Prefix:	ions_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

The potential premium received if common stock is purchased in the future at a premium under a Stock Purchase Agreement (SPA) in conjunction with the collaboration agreement.

No definition available.

Name:	ions_PotentialPremiumReceivedIfCommonStockIsPurchasedInTheFutureAtAPremium
Namespace Prefix:	ions_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

The total amount of the premium received over the trading price of common stock at the time of purchase.

No definition available.

Name:	ions_PremiumReceivedOnSharesIssued
Namespace Prefix:	ions_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

Represents the number of separate units of accounting requiring the allocation of consideration for revenue recognition purposes under the multi-deliverable arrangement.

No definition available.

Name:	ions_RevenueRecognitionMultiDeliverableArrangementNumberOfUnitsOfAccounting
Namespace Prefix:	ions_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

Royalty percentage received on the sales of a drug by a collaboration partner under the collaboration agreement.

No definition available.

Name:	ions_RoyaltyPercentageReceivedOnSalesOfDrug
Namespace Prefix:	ions_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

The amount of upfront payments received during the period under the collaboration agreement.

No definition available.

Name:	ions_UpfrontPaymentReceived
Namespace Prefix:	ions_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.4(a).Q1)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Name:	us-gaap_DeferredRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

The cash inflow from the additional capital contribution to the entity.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Financing Activities
-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3255-108585

Name:	us-gaap_ProceedsFromIssuanceOfCommonStock
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

Name:	us-gaap_Revenues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

Number of new stock issued during the period.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Name:	us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

Name:	us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_RangeAxis=us-gaap_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_ProductOrServiceAxis=ions_AKCEAAPOALMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_ProductOrServiceAxis=ions_AKCEAAPOCIIILMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: